SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing intense volatility as shareholders push for leadership changes and express frustration over slumping sales, high inventory levels, and a perceived disconnection from modern consumer trends. The market is deeply divided ahead of its earnings release, with a significant cohort of traders actively shorting the stock, while others view its recent descent to multi-year lows as a potential, though highly risky, entry point for a long-term turnaround.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming 10-K filing and earnings report, with the community closely tracking the company's aggressive debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish sentiment remains high as retail participants anticipate a potential valuation re-rating driven by balance sheet improvements and a possible short squeeze.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility as investors weigh the company's exposure to ongoing tariff risks against its ambitious international expansion and long-term luxury strategy. The community remains deeply divided, with some traders betting on a short squeeze or a valuation recovery, while others express skepticism over the firm's leadership and the sustainability of its high-end furniture pricing in a strained economic environment.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors monitor the early commercial rollout of Yartemlea and anticipate further clarity on revenue ramp and European regulatory progress. The community remains focused on potential milestone payments from the partnership with Novo Nordisk and the company's long-term potential as a commercial-stage biotech, despite current frustration over recent share price volatility and limited official guidance.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing intense community debate as investors weigh the company's transition from R&D to production-scale manufacturing, with recent chatter heavily focused on interpreting potential indirect ties to major industry players like NVIDIA and Marvell. While bulls emphasize the strategic long-term value of their optical interposer technology and validated partnerships, bears remain vocal about the lack of significant near-term revenue and the ongoing dilution risk that has fueled skepticism regarding management's execution.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is currently a focal point for investors due to its high short interest and speculative potential for a short squeeze, despite ongoing concerns about its business model and the impact of discretionary spending shifts. The community is actively debating the company's turnaround strategy under new leadership while weighing the risks of its significant debt levels against the possibility of institutional share accumulation.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is driving significant engagement through a coordinated social campaign to increase visibility and brand awareness. Discussions are largely centered around community building, frequent meme-style interaction, and encouraging new participants to join their ecosystem.

Tema ETF Trust - Tema Space Innovators ETF

Investors are closely tracking NASA for its strategic exposure to the burgeoning space economy, with particular interest in its significant holdings in companies connected to private aerospace ventures. The community is actively discussing the ETF's portfolio composition and its potential to capture long-term growth within the specialized space innovation sector.

Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.

ORIC Pharmaceuticals Inc

ORIC Pharmaceuticals is drawing intense community attention due to a strategic clinical development collaboration with Pfizer for its multiple myeloma candidate, which includes a 25 million dollar equity investment at a premium. Investors are actively debating the stock's potential for a short squeeze given the high short interest and institutional backing, with many focusing on the validation this deal provides for the company's oncology pipeline.

THE FAMOUS DOG JUMPING INTO THE WATER FROM TIKTOK WITH 500M+ VIEWS.  A few facts about me - Signature Pool Dive - Serial Killer - Silly  Roadmap 1. BORN - Launch of a token, development of a family of holders and a twitter 2.BORN - Project development, marketing and connect KOLs 3. CEX listings - Listing on top exchanges and partnerships  Being a memecoin doesn’t mean we won’t have utilities. Our developers will develop some fun and useful tools for its community members as we continue to BUIDL! Our main goal is to make sure everyone has access to our utilities, so we build it with scalability in mind.  Ready to Splash?

Splash Dog

BUSTER CRYPTO is gaining momentum within the Solana ecosystem as community members rally behind the token and express strong bullish sentiment regarding its growth potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Best Mid Cap Stocks To Watch Today - March 31st

ProShares UltraPro Short QQQ, Apellis Pharmaceuticals, Centessa Pharmaceuticals, Applied Optoelectronics, and Direxion Daily TSLA Bull 2X Shares are the five Mid Cap stocks to watch today, according to MarketBeat's stock screener tool. Mid-cap stocks are shares of companies with market capitalizati...

Noteworthy Tuesday Option Activity: APLS, AMTM, EXP

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Apellis Pharmaceuticals Inc (Symbol: APLS), where a total volume of 23,358 contracts has been traded thus far today, a contract volume which is representative of...

Pharmaceutical Stocks To Watch Today - March 31st

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Eli Lilly and Company, AbbVie, Pfizer, Abbott Laboratories, and Novo Nordisk A/S are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that r...

Medical Stocks To Add to Your Watchlist - March 31st

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Eli Lilly and Company, UnitedHealth Group, Boston Scientific, AbbVie, and Pfizer are the seven Medical stocks to watch today, according to MarketBeat's stock screener tool. Medical stocks are shares of companies involved in healthcare including p...

Apellis Pharmaceuticals (NASDAQ:APLS) Receives "Hold" Rating from Needham & Company LLC

Needham & Company LLC reissued a "hold" rating on shares of Apellis Pharmaceuticals in a research note on Tuesday...

Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders

Shareholder Alert: The Ademi Firm investigates whether Apellis Pharmaceuticals Inc. is obtaining a Fair Price for Public Shareholders Shareholder Alert: The Ademi Firm investigates whether Apellis...

Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders?

Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders? Are APLS, CNTA, BIRD Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, March 31, 2026 Insiders may stand to receive...

Apellis Pharmaceuticals (NASDAQ:APLS) Sets New 1-Year High - Here's Why

Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 1-Year High - Time to Buy...

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave...

Futures Jump On Hopes Of War De-escalation, Korea Enters Bear Market On Memory Rout

Futures Jump On Hopes Of War De-escalation, Korea Enters Bear Market On Memory Rout

 Futures are higher on a WSJ report that Trump is considering exiting the middle east conflict even if the Strait of Hormuz is not reopened; but the market is deciding whether this is a genuine intent to...

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Stocktwits

Stocktwits Polls

Biogen has agreed to acquire Apellis for $5.6 billion at $41 per share, sparking a massive rally and major celebration among long-term shareholders.

The surprise acquisition announcement caught heavy short interest by total surprise, resulting in massive liquidations for those betting against the stock.

Traders are actively scouting for the next acquisition target in the biotech space following recent major industry deals.

Investors are closely analyzing the non-transferrable Contingent Value Rights included in the buyout deal for additional future upside.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.34	--	--	N/A
Q4 '25	-$0.38	-$0.47	-24.25%	MISSED
Q3 '25	$1.58	$1.67	5.78%	BEAT
Q2 '25	-$0.48	-$0.33	31.64%	BEAT
Q1 '25	-$0.35	-$0.74	-109.74%	MISSED

APLS
Apellis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest APLS News

APLSApellis Pharmaceuticals Inc